CareDx Reports Q3 Earnings Beat with Significant Revenue Growth and Raised 2026 Guidance
CareDx (NASDAQ: CDNA) reported third-quarter financial results that significantly exceeded market expectations. The company posted a Non-GAAP earnings per share (EPS) of $0.70, surpassing estimates by $0.44, while revenue reached $139 million, representing a 39% increase year-over-year and beating projections by over $17 million. Building on this momentum, CareDx updated its long-term outlook, projecting full-year 2026 revenue to fall within the range of $520 million to $530 million. The strong quarterly performance and upwardly revised guidance signal robust growth in the company's transplant diagnostics business.
Tickers: $CDNA
Topics: earnings beat guidance revenue growth